Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy
L. Gorska, M. Chelminska, K. Kuziemski, M. Skrzypska, M. Niedoszytko, I. Damps-Kostanska, A. Szymanowska, A. Sieminska, B. Wajda, A. Drozdowska, M. Jutel, E. Jassem (Gdansk, Wroclaw, Poland)
Source: Annual Congress 2008 - Allergy and immunology of asthma and beyond
Session: Allergy and immunology of asthma and beyond
Session type: Thematic Poster Session
Number: 3740
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Gorska, M. Chelminska, K. Kuziemski, M. Skrzypska, M. Niedoszytko, I. Damps-Kostanska, A. Szymanowska, A. Sieminska, B. Wajda, A. Drozdowska, M. Jutel, E. Jassem (Gdansk, Wroclaw, Poland). Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Eur Respir J 2008; 32: Suppl. 52, 3740
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Evaluation and efficacy of allergen immunotherapy in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 399s Year: 2005
Allergen specific immunotherapy efficacy in children with pollen-food allergy syndrome and different IgE profiles to recombinant component-resolved allergens. Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Allergen immunotherapy: therapeutic vaccines for allergic diseases Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=409 Year: 2003
Investigation of gene expression in relation to omalizumab treatment and peanut oral immunotherapy Source: Virtual Congress 2021 – Biomarkers and risk factors in childhood asthma Year: 2021
Specific immunotherapy with high dose grass allergen tablets was safe in grass pollen induced asthma Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005
Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Allergen avoidance and allergic sensitisation: current views and controversies Source: Annual Congress 2005 - MP3 - Allergen avoidance and allergic sensitisation: current views and controversies Year: 2005
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Confirmed clinical safety and efficacy of grass allergen tablets Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005
Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Effect of allergen-specific immunotherapy on platelet secretory activity in patients with house-dust mite allergy Source: Eur Respir J 2007; 30: Suppl. 51, 369s Year: 2007
Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021
The specific methods of immunotherapy in treatment of the patients with allergic seasonal rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 507s Year: 2002
Sublingual allergen specific immunotherapy in children with respiratory allergies – long lasting efficacy Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002
Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Serum angiotensin converting enzyme (ACE) in hymenoptera venom allergic patients with specific immunotherapy (SIT) Source: Eur Respir J 2007; 30: Suppl. 51, 268s Year: 2007
Sublingual specific immunotherapy in the treatment of hay fever caused by tree pollen in children Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases Year: 2010
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007